We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure
Read MoreHide Full Article
Key Takeaways
XRAY topped Q2 earnings and revenue estimates while maintaining its full-year 2026 outlook.
Wellspect Healthcare grew 7.1%, offsetting declines across XRAY's three dental segments.
XRAY improved gross and EBITDA margins, but operating margin fell amid tariffs and lower volumes.
DENTSPLY SIRONA Inc. (XRAY - Free Report) topped second-quarter 2026 earnings and revenue expectations while keeping its full-year outlook intact. The results showed better cash generation and selected margin gains, but they did not mark a broad recovery in dental demand.
The post-earnings question is whether those improvements can outweigh falling sales, tariff pressure and continued weakness in equipment, orthodontics and implants. Wellspect Healthcare remained the clearest growth offset.
XRAY’s Q2 Beat Came With Lower Revenue
Adjusted earnings of 52 cents per share beat the Zacks Consensus Estimate of 36 cents by 44.4%. Revenues of $898 million topped the consensus estimate by 1.6%.
That beat came despite revenues falling 4.1% year over year as reported and 6.3% at constant currency. Weakness across three dental segments and the absence of Byte kept the quarter from signaling a broad sales recovery.
Wellspect Healthcare revenues rose 7.1% to $86 million, supported by new product launches. Connected Technology Solutions fell 1.5%, Essential Dental Solutions declined 2.7% and Orthodontic and Implant Solutions dropped 13.2%.
The wider dental market is mixed. Align Technology, Inc. (ALGN - Free Report) reported 8.2% growth in second-quarter clear-aligner revenues, but its Imaging Systems and computer-aided design and manufacturing services revenues fell 10.8%. Envista Holdings Corporation (NVST - Free Report) reported 5.0% core sales growth, showing that industry demand is uneven rather than uniformly weak.
XRAY’s Margins Show a Mixed but Better Picture
Adjusted gross margin improved 50 basis points to 56.4%, while adjusted EBITDA margin increased 20 basis points to 21.3%. Tariff refunds helped both measures.
Adjusted operating margin, however, contracted 240 basis points to 15.8%. Lower volumes, unfavorable mix, tariff costs and higher selling, general and administrative expenses and increased research and development spending continued to limit operating leverage.
XRAY’s Cash Flow Improves as Liquidity Tightens
Second-quarter free cash flow increased to $55 million from $16 million a year earlier. First-half operating cash flow rose to $139 million from $55 million, aided by tariff refunds and better management of inventory and accounts payable.
Cash and cash equivalents stood at $239 million at June 30, down from $326 million at Dec. 31, 2025. The net debt-to-EBITDA ratio was 3.2, keeping balance-sheet flexibility and debt reduction important to the turnaround.
DENTSPLY SIRONA Inc. Cash from Operations (Quarterly)
Dentsply Sirona maintained its 2026 net sales outlook of $3.5 billion to $3.6 billion and adjusted earnings guidance of $1.40-$1.50 per share. Benefits from tariff refunds are excluded from the adjusted earnings outlook.
Maintaining guidance gives investors a clear second-half benchmark. A more durable recovery still depends on better equipment demand, stabilization in SureSmile and implants and improved conversion from the company’s expanded dealer network and commercial investments.
XRAY’s Scores Keep the Post-Earnings View Balanced
The quarter supports a measured view rather than a clean turnaround call. Better cash flow and some margin improvement are constructive, but sales contraction, tariffs and execution risk remain meaningful.
XRAY currently carries a Zacks Rank #3 (Hold), with a Value Score of A, Growth Score of B, Momentum Score of F and VGM Score of B. The Value Score of A, Growth Score of B and VGM Score of B point to relatively favorable value, growth and blended characteristics, while the Momentum Score of F signals weak near-term momentum. Combined with a Hold rank, the setup remains balanced. While Envista Holdings sports a Zacks Rank #1 (Strong Buy), Align Technology carries a Zacks Rank of 3.You can see the complete list of today’s Zacks #1 Rank stocks here.
View the Zacks #1 Rank List
Image: Bigstock
XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure
Key Takeaways
DENTSPLY SIRONA Inc. (XRAY - Free Report) topped second-quarter 2026 earnings and revenue expectations while keeping its full-year outlook intact. The results showed better cash generation and selected margin gains, but they did not mark a broad recovery in dental demand.
The post-earnings question is whether those improvements can outweigh falling sales, tariff pressure and continued weakness in equipment, orthodontics and implants. Wellspect Healthcare remained the clearest growth offset.
XRAY’s Q2 Beat Came With Lower Revenue
Adjusted earnings of 52 cents per share beat the Zacks Consensus Estimate of 36 cents by 44.4%. Revenues of $898 million topped the consensus estimate by 1.6%.
That beat came despite revenues falling 4.1% year over year as reported and 6.3% at constant currency. Weakness across three dental segments and the absence of Byte kept the quarter from signaling a broad sales recovery.
DENTSPLY SIRONA Inc. Revenue (Quarterly)
DENTSPLY SIRONA Inc. revenue-quarterly | DENTSPLY SIRONA Inc. Quote
XRAY’s Wellspect Unit Provided the Bright Spot
Wellspect Healthcare revenues rose 7.1% to $86 million, supported by new product launches. Connected Technology Solutions fell 1.5%, Essential Dental Solutions declined 2.7% and Orthodontic and Implant Solutions dropped 13.2%.
The wider dental market is mixed. Align Technology, Inc. (ALGN - Free Report) reported 8.2% growth in second-quarter clear-aligner revenues, but its Imaging Systems and computer-aided design and manufacturing services revenues fell 10.8%. Envista Holdings Corporation (NVST - Free Report) reported 5.0% core sales growth, showing that industry demand is uneven rather than uniformly weak.
XRAY’s Margins Show a Mixed but Better Picture
Adjusted gross margin improved 50 basis points to 56.4%, while adjusted EBITDA margin increased 20 basis points to 21.3%. Tariff refunds helped both measures.
Adjusted operating margin, however, contracted 240 basis points to 15.8%. Lower volumes, unfavorable mix, tariff costs and higher selling, general and administrative expenses and increased research and development spending continued to limit operating leverage.
XRAY’s Cash Flow Improves as Liquidity Tightens
Second-quarter free cash flow increased to $55 million from $16 million a year earlier. First-half operating cash flow rose to $139 million from $55 million, aided by tariff refunds and better management of inventory and accounts payable.
Cash and cash equivalents stood at $239 million at June 30, down from $326 million at Dec. 31, 2025. The net debt-to-EBITDA ratio was 3.2, keeping balance-sheet flexibility and debt reduction important to the turnaround.
DENTSPLY SIRONA Inc. Cash from Operations (Quarterly)
DENTSPLY SIRONA Inc. cash-from-operations-quarterly | DENTSPLY SIRONA Inc. Quote
XRAY Keeps 2026 Guidance Despite Uneven Demand
Dentsply Sirona maintained its 2026 net sales outlook of $3.5 billion to $3.6 billion and adjusted earnings guidance of $1.40-$1.50 per share. Benefits from tariff refunds are excluded from the adjusted earnings outlook.
Maintaining guidance gives investors a clear second-half benchmark. A more durable recovery still depends on better equipment demand, stabilization in SureSmile and implants and improved conversion from the company’s expanded dealer network and commercial investments.
XRAY’s Scores Keep the Post-Earnings View Balanced
The quarter supports a measured view rather than a clean turnaround call. Better cash flow and some margin improvement are constructive, but sales contraction, tariffs and execution risk remain meaningful.
XRAY currently carries a Zacks Rank #3 (Hold), with a Value Score of A, Growth Score of B, Momentum Score of F and VGM Score of B. The Value Score of A, Growth Score of B and VGM Score of B point to relatively favorable value, growth and blended characteristics, while the Momentum Score of F signals weak near-term momentum. Combined with a Hold rank, the setup remains balanced. While Envista Holdings sports a Zacks Rank #1 (Strong Buy), Align Technology carries a Zacks Rank of 3.You can see the complete list of today’s Zacks #1 Rank stocks here.